Whalesbook
The Central Government Health Scheme's (CGHS) reimbursement policy caps hospital payments at 70% of the Maximum Retail Price (MRP) for essential high-cost oncology medicines. This creates significant financial pressure for private healthcare providers, forcing them to cover the remaining 30% deficit. With profit margins for these specialized treatments often between 10-15%, this shortfall is becoming unsustainable. The Association of Healthcare Providers (India) (AHPI) has alerted the health ministry to this growing problem, noting that nine specific patented immunotherapy drugs are now harder for CGHS beneficiaries to access.
The Price Discrepancy
The main problem is the large difference between the actual cost of patented immunotherapy drugs and the government's reimbursement limit. For example, Keytruda, a vital immunotherapy drug, costs about ₹1.5 lakh per 100 mg vial in India. Monthly treatment can cost over ₹3 lakh. Under the CGHS policy, hospitals only receive 70% of the MRP, meaning they must pay the other 30%. This deficit adds up significantly for advanced treatments. The Indian oncology drug market is expected to grow, driven by more cancer cases and demand for advanced therapies. However, reimbursement frameworks are a major obstacle, accounting for over 60% of what patients pay out-of-pocket.
Operational and Legal Hurdles
Hospitals find the current reimbursement process difficult to manage practically and legally. One option is billing CGHS at the full MRP but only receiving 70%, which directly hurts their finances. Many hospitals buy these patented drugs through complex bulk contracts with pharmaceutical companies. These contracts often forbid disclosing negotiated prices to others. Submitting purchase invoices to CGHS could therefore lead to contract breaches and potentially supply disruptions from drug manufacturers. Asking patients to buy their own medicines is another option, but it's medically risky due to strict cold chain needs and the difficulty patients have in ensuring the drugs are genuine. Also, the CGHS supply chain has historically faced reported delays and shortages, leading to disrupted treatment schedules and poorer patient outcomes.
Financial Strain on Private Hospitals
Government health schemes, including CGHS, typically bring in a large share of revenue for major private hospital networks, estimated at 20-25%. However, this share is declining. Analysts expect revenue from these schemes could drop another 3-5% by the first quarter of fiscal year 2027 as hospitals strategically reduce participation or limit bed availability. Major hospital chains have reported significant financial impacts; Max Healthcare, for instance, noted a ₹200 crore revenue impact from its CGHS engagement. This financial adjustment is visible in market valuations. Max Healthcare has a market capitalization of about ₹98,871 crore (P/E ~140.81), and Apollo Hospitals is at ₹111,253 crore (P/E ~60.93) as of early May 2026. However, high P/E ratios for some, like Fortis Healthcare at ₹71,687 crore (P/E ~439.54) and HealthCare Global Enterprises (HCG) at ₹8,612 crore (P/E ~429.50), may signal investor concern about profitability given these scheme issues.
Policy Updates and Ongoing Issues
CGHS reimbursement rates have historically been a source of disagreement. Before a major update in October 2025, rates for many procedures had not changed since 2014. The October 2025 update introduced a tiered, quality-linked pricing structure, tying reimbursement to hospital accreditation, city tier, and ward entitlement. This reform aimed to help finances and improve access. While these changes may help with some services, the core problem of a 70% MRP cap on specific high-cost patented drugs for advanced cancer therapy remains a major obstacle. AHPI has repeatedly pushed for reimbursement at the full MRP for these essential medicines, highlighting the continued gap in policy.
Hospital Concerns and Past Issues
Private hospitals have long faced challenges with government reimbursement schemes. The Association of Healthcare Providers (India) (AHPI) has previously reported significant pending dues, exceeding ₹500 crore owed to over 60 private hospitals. Additionally, reimbursement rates have often seen long delays, with some not revised for many years prior to the October 2025 update. These ongoing issues highlight a persistent friction between healthcare providers and the government's payment mechanisms.
Impact on Private Providers
This policy environment creates a structural difficulty for private providers who rely on government schemes for a considerable part of their revenue. Unlike private insurance or self-paying patients who offer higher profit margins, the CGHS reimbursement cap for life-saving patented drugs puts hospitals in a difficult financial position. This can discourage them from offering these advanced treatments. While the overall Indian oncology market is growing, the lack of adequate reimbursement frameworks for cancer treatments presents a major barrier to patient access.
Key Risks
The primary risk is severely reduced patient access to critical, life-saving immunotherapy drugs due to cost and reimbursement shortfalls. Hospitals also face the risk of breaching contracts with pharmaceutical manufacturers if they cannot comply with price disclosure rules, potentially leading to supply chain disruptions for essential medicines. Furthermore, the sustained financial pressure on hospitals, as seen in the market valuations and P/E ratios of some major chains, could affect their long-term ability to invest in advanced infrastructure and maintain overall healthcare quality. This policy paradox risks undermining efforts to expand access to advanced cancer care.